We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline of presentation
- Central nervous system diseases
- Drug market for CNS disorders
- Traditional CNS drug targets
- Novel CNS drug targets
- Multiple obstacles for drug delivery to CNS
- Pathways for drug exchange within the CNS
- Factors affecting brain drug delivery and exchange
- The structure of brain capillaries impedes uptake
- Measures of drug uptake and distribution in brain
- BBB permeability and solute lipid solubility
- Tissues capillary PS and 95% equilibration time
- Cerebral blood flow affects drug uptake and Kin
- Initial uptake vs. steady-state distribution
- Plasma protein binding and brain drug uptake
- Example of the impact of plasma protein binding
- Brain capillary drug transporters
- Transporters and drug distribution across BBB
- "Enzymatic" blood-brain barrier
- Drug distribution in brain at steady state
- Relation between bound and free drug
- Free drug distribution ratio at steady state
- BBB changes in pathology and disease
- Drug-like properties to cross the BBB
- Early findings in BBB drug uptake
- Measures of lipophilicity
- Passive permeability across lipid membranes
- Drug ionization
- Influence of pH on neutral fraction
- Lipinski "rule of five"
- "Rule of five" modified for CNS drugs
- Impact of hydrogen bonds and alkyl groups
- Examples of positive CNS drugs
- Example of a poor CNS drug
- Other in vitro measures
- In vivo measures
- Methods to improve brain uptake
- Simple rules for efflux transporters
- % drug distribution to brain
- Biologic compounds
- Closing comments of brain pharmacokinetics
- Summary
- Acknowledgements
Topics Covered
- Central nervous system diseases
- Drug market for CNS disorders
- Traditional CNS drug targets
- Novel CNS drug targets
- Multiple obstacles for drug delivery to CNS
- Pathways for drug exchange within the CNS
- The structure of brain capillaries impedes uptake
- Measures of drug uptake and distribution in brain
- BBB permeability and solute lipid solubility
- Tissues capillary PS and 95% equilibration time
- Cerebral blood flow affects drug uptake and Kin
- Initial uptake vs. steady-state distribution
- Plasma protein binding and brain drug uptake
- Brain capillary drug transporters
- Transporters and drug distribution across BBB
- "Enzymatic" blood-brain barrier
- Relation between bound and free drug
- Free drug distribution ratio at steady state
- BBB changes in pathology and disease
- Drug-like properties to cross the BBB
- Early findings in BBB drug uptake
- Measures of lipophilicity
- Passive permeability across lipid membranes
- Drug ionization
- Influence of pH on neutral fraction
- Lipinski "rule of five"
- Impact of hydrogen bonds and alkyl groups
- Positive CNS drugs
- Poor CNS drug
- in vitro measures
- In vivo measures
- Methods to improve brain uptake
- Simple rules for efflux transporters
- % drug distribution to brain
- Biologic compounds
- Brain pharmacokinetics
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Smith, Q. (2008, March 1). CNS-drug design [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/EJEM3763.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Quentin Smith has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.